Scientific advisor

CESARE GALLI

Scientific advisor

MARC BOUILLET

M.D., former partner/CEO in several pharmaceutical companies and patient associations

An agile company with a fast-paced development

XENOTHERA is a biotechnology start-up company at the top of innovation, which creates new therapeutic modes in numerous domains from immunomodulation to infectious diseases.

Our technological platform is built on a double expertise of animal genetics and mastery of immunological processes. It renovates passive immunotherapy by marketing a new generation of hyperimmune polyclonal sera.
Our antibodies are engineered to display specific properties with reduced adverse effects and enhanced biological properties.

XENOTHERA’s platform ensures short-time development thanks to our mastery of the entire process, from animal genetics, choice of the immunogen, selection and purification of antibodies, and access to market authorization in accelerated timescale.

Xenothera is a start-up in biotechnology, specialized in immunology, infectious diseases and oncology

Investors already trusted us in 2014 and 2016 by funding the company for 4M€. We are raising an additional 10M€ in 2018 to complete the first-in-man clinical trial of our first product. Our products will offer a substantial patient benefit and address unsolved major public health issues